Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced ...
Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago...
PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced castration resistant prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )
7 Nov 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
Highlights from ESMO 2019 ( Prof Josep Tabernero - ESMO President )
4 Oct 2019
Prostate cancer updates: Advances in precision medicine and PARP inhibitors
Prof Karim Fizazi, Dr Joaquin Mateo, Dr Shahneen Sandhu and Prof Bertrand Tombal
Prostate cancer updates: Advances in precision medicine and PARP inhibitors ( Prof Karim Fizazi, Dr Joaquin Mateo, Dr Shahneen Sandhu and Prof Bertrand Tombal )
2 Oct 2019
Breast cancer highlights from ESMO 2019
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer highlights from ESMO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
2 Oct 2019
Melanoma highlights from ESMO 2019
Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany
Melanoma highlights from ESMO 2019 ( Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany )
30 Sep 2019
PARP inhibitor olaparib slows progression of advanced prostate cancer
Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago...
PARP inhibitor olaparib slows progression of advanced prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )
30 Sep 2019
Comment: PARP inhibitors for advanced prostate cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: PARP inhibitors for advanced prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019
Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )
30 Sep 2019
MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer
Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA
MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA )
29 Sep 2019
Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenop...
Prof George Sledge - Stanford Health Care, Stanford, USA
Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy ( Prof George Sledge - Stanford Health Care, Stanford, USA )
29 Sep 2019
Providing quality patient care and service using the Oncology Care Model
Dr Vedner Guerrier - Memorial Healthcare System, Hollywood, FL, USA
Providing quality patient care and service using the Oncology Care Model ( Dr Vedner Guerrier - Memorial Healthcare System, Hollywood, FL, USA )
26 Jul 2019
BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-m...
Prof Hope Rugo - University of California, San Francisco, USA
BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )
12 Jun 2019